Search Results 1151-1160 of 21715 for Inhibition

1. Patient-Reported Outcome Questionnaire for Use Among Patients with Myelofibrosis After First Line Treatment Failure - Mayo Clinic

   Prior treatment with a licensed or experimental smoothened inhibitor (SMOi); Targeted anti‐cancer therapy up to 14 days prior to enrolment (note prior ...

2. Publications - Carlos B. Mantilla, M.D., Ph.D. - Mayo Clinic

   Inhibition of TrkB kinase activity impairs autophagy in cervical motor neurons of young but not old mice. Exp Physiol. 2025 Jan; 110 (1):166-178 Epub 2024 ...

3. J.C. C. Villasboas Bisneto, M.D. - Mayo Clinic Faculty Profiles

   Aggressive NHLs are cancers that often fail to be cured by standard chemotherapy. Newer generation immunotherapy agents, such as checkpoint inhibitors, have ...

4. Endoxifen Shows Promise as Breast Cancer Treatment - Mayo Clinic News Network

   We have seen evidence for tumor regression in patients who had failed standard hormonal therapies including aromatase inhibitors, fulvestrant and tamoxifen.

5. A Study to Evaluate Immune-related Biomarkers for Pathological Response in Stage II-III HER2-positive Breast Cancer - Mayo Clinic

   ... inhibitors) for their cancer. 3.29 Known history of active autoimmune disease that has required systemic treatment in the ≤30 days (i.e., with use of ...

6. Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim 2) - Mayo Clinic

   About this study. To determine the effect of 12 weeks of chronic PDEV inhibition with Tadalafil versus placebo on basal cardiorenal and humoral function and ...

7. Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer - Mayo Clinic

   Participants receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 or moderate inhibitors of CYP3A4 are ineligible; the ...

8. A Study to Evaluate Durvalumab plus Topotecan or Lurbinectedin in Patients with Small Cell Lung Cancer - Mayo Clinic

   ... inhibitor regimen;; Prior therapy must have been an etoposide platinum doublet combined with PD-1 or PD-L1 inhibitor;; Must have "platinum-sensitive" disease ...

9. A Study of Poziotinib in Patients with NSCLC With EGFR or HER2 Exon 20 Insertion Mutation - Mayo Clinic

   Patient has had previous treatment with poziotinib or any other EGFR or HER2 exon 20 insertion mutation-selective tyrosine kinase inhibitor (TKI) prior to study ...

10. Study of INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma - Mayo Clinic

    Known hypersensitivity allergy or contraindication to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the PD-1/PD-L1 inhibitor ...